{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:25:14Z","timestamp":1791379514713,"version":"4.3.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41397-024-00341-2","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T19:03:00Z","timestamp":1718996580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive role of ITPA genetic variants in thiopurine-related myelotoxicity in Crohn\u2019s disease patients"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3581-4499","authenticated-orcid":false,"given":"Juliana","family":"Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-3927","authenticated-orcid":false,"given":"Pau","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gordillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-8449","authenticated-orcid":false,"given":"Albert","family":"Alt\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-1160","authenticated-orcid":false,"given":"Miguel","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Ser\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordina","family":"Lla\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-2529","authenticated-orcid":false,"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garcia-Planella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"341_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607. https:\/\/doi.org\/10.1136\/gut.2010.224154","journal-title":"Gut"},{"key":"341_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ajg.2011.401","volume":"107","author":"S Chatu","year":"2012","unstructured":"Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn\u2019s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:23\u201334. https:\/\/doi.org\/10.1038\/ajg.2011.401","journal-title":"Am J Gastroenterol"},{"key":"341_CR3","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1038\/ajg.2009.301","volume":"104","author":"L Peyrin-Biroulet","year":"2009","unstructured":"Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn\u2019s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089\u201396. https:\/\/doi.org\/10.1038\/ajg.2009.301","journal-title":"Am J Gastroenterol"},{"key":"341_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u201395. https:\/\/doi.org\/10.1056\/NEJMoa0904492","journal-title":"N Engl J Med"},{"key":"341_CR5","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","volume":"19","author":"M Chaparro","year":"2013","unstructured":"Chaparro M, Pan\u00e9s J, Garc\u00eda V, Mendoza JL, Bermejo F, L\u00f3pez San Rom\u00e1n A, et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404\u201310. https:\/\/doi.org\/10.1097\/MIB.0b013e318281f28f","journal-title":"Inflamm Bowel Dis"},{"key":"341_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00008571-200208000-00003","volume":"12","author":"M Schwab","year":"2002","unstructured":"Schwab M, Sch\u00e4ffeler E, Marx C, Fischer C, Lang T, Behrens C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002;12:429\u201336. https:\/\/doi.org\/10.1097\/00008571-200208000-00003","journal-title":"Pharmacogenetics"},{"key":"341_CR7","doi-asserted-by":"publisher","first-page":"CD000545","DOI":"10.1002\/14651858.CD000545.pub5","volume":"10","author":"N Chande","year":"2013","unstructured":"Chande N, Laidlaw M, McDonald JW, Macdonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2013;10:CD000545 https:\/\/doi.org\/10.1002\/14651858.CD000545.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"341_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/1756-185X.12204","volume":"17","author":"AB Friedman","year":"2014","unstructured":"Friedman AB, Sparrow MP, Gibson PR. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders. Int J Rheum Dis. 2014;17:132\u201341. https:\/\/doi.org\/10.1111\/1756-185X.12204","journal-title":"Int J Rheum Dis"},{"key":"341_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","volume":"91","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"341_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2036.2011.04905.x","volume":"35","author":"L Chouchana","year":"2012","unstructured":"Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:15\u201336. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04905.x","journal-title":"Aliment Pharmacol Ther"},{"key":"341_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/pgs.09.155","volume":"11","author":"JE Higgs","year":"2010","unstructured":"Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010;11:177\u201388. https:\/\/doi.org\/10.2217\/pgs.09.155","journal-title":"Pharmacogenomics"},{"key":"341_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.2003.01690.x","volume":"18","author":"RB Gearry","year":"2003","unstructured":"Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:395\u2013400. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01690.x","journal-title":"Aliment Pharmacol Ther"},{"key":"341_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0016-5085(00)70354-4","volume":"118","author":"JF Colombel","year":"2000","unstructured":"Colombel JF, Ferrari N, Debuys\u00e8re H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025\u201330. https:\/\/doi.org\/10.1016\/S0016-5085(00)70354-4","journal-title":"Gastroenterology"},{"key":"341_CR14","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1046\/j.1365-2036.2002.01353.x","volume":"16","author":"A Ansari","year":"2002","unstructured":"Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743\u201350. https:\/\/doi.org\/10.1046\/j.1365-2036.2002.01353.x","journal-title":"Aliment Pharmacol Ther"},{"key":"341_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","volume":"111","author":"S Sumi","year":"2002","unstructured":"Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre EM, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111:360\u20137. https:\/\/doi.org\/10.1007\/s00439-002-0798-z","journal-title":"Hum Genet"},{"key":"341_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00008571-200403000-00006","volume":"14","author":"AM Marinaki","year":"2004","unstructured":"Marinaki AM, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-Bakre M, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14:181\u20137. https:\/\/doi.org\/10.1097\/00008571-200403000-00006","journal-title":"Pharmacogenetics"},{"key":"341_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48:367\u201373. https:\/\/doi.org\/10.1038\/ng.3508","journal-title":"Nat Genet"},{"key":"341_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cpt.1411","volume":"105","author":"JJ Yang","year":"2019","unstructured":"Yang JJ, Whirl-Carrillo M, Scott SA, Turner AJ, Schwab M, Tanaka Y, et al. Pharmacogene variation consortium gene introduction: NUDT15. Clin Pharmacol Ther. 2019;105:1091\u20134. https:\/\/doi.org\/10.1002\/cpt.1411","journal-title":"Clin Pharmacol Ther"},{"key":"341_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144\u201364. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy113","journal-title":"J Crohns Colitis"},{"key":"341_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5\u201336.","journal-title":"Can J Gastroenterol"},{"key":"341_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","volume":"1","author":"RF Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM. A simple index of Crohn\u2019s disease activity. Lancet. 1980;1:514.","journal-title":"Lancet"},{"key":"341_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1365-2036.2002.01177.x","volume":"16","author":"S Campbell","year":"2002","unstructured":"Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther. 2002;16:389\u201398. https:\/\/doi.org\/10.1046\/j.1365-2036.2002.01177.x","journal-title":"Aliment Pharmacol Ther"},{"key":"341_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cgh.2005.10.019","volume":"4","author":"Z Zelinkova","year":"2006","unstructured":"Zelinkova Z, Derijks LJ, Stokkers PC, Vogels EW, van Kampen AH, Curvers WL, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol. 2006;4:44\u201349. https:\/\/doi.org\/10.1016\/j.cgh.2005.10.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"341_CR24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.clinbiochem.2011.06.079","volume":"44","author":"O Dewit","year":"2011","unstructured":"Dewit O, Moreels T, Baert F, Peeters H, Reenaers C, de Vos M, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem. 2011;44:1062\u20136. https:\/\/doi.org\/10.1016\/j.clinbiochem.2011.06.079","journal-title":"Clin Biochem"},{"key":"341_CR25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1365-2036.2008.03788.x","volume":"28","author":"A Ansari","year":"2008","unstructured":"Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:973\u201383. https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03788.x","journal-title":"Aliment Pharmacol Ther"},{"key":"341_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/gut.2005.074930","volume":"55","author":"U Hindorf","year":"2006","unstructured":"Hindorf U, Lindqvist M, Peterson C, S\u00f6derkvist P, Str\u00f6m M, Hjortswang H, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55:1423\u201331. https:\/\/doi.org\/10.1136\/gut.2005.074930","journal-title":"Gut"},{"key":"341_CR27","first-page":"1664","volume":"54","author":"JM Van Dieren","year":"2005","unstructured":"Van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut. 2005;54:1664.","journal-title":"Gut"},{"key":"341_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/MCG.0000000000001791","volume":"57","author":"M Guti\u00e9rrez-Valencia","year":"2023","unstructured":"Guti\u00e9rrez-Valencia M, Leache L, Saiz LC, Beloqui JJ, Barajas M, Vicu\u00f1a M, et al. Role of pharmacogenomics in the efficacy and safety of thiopurines in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2023;57:671\u201385.","journal-title":"J Clin Gastroenterol"},{"key":"341_CR29","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1373\/clinchem.2005.057158","volume":"51","author":"N Von Ahsen","year":"2005","unstructured":"Von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, et al. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem. 2005;51:2282\u20138. https:\/\/doi.org\/10.1373\/clinchem.2005.057158","journal-title":"Clin Chem."},{"key":"341_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/apt.14494","volume":"47","author":"M Ma\u00f1osa","year":"2018","unstructured":"Ma\u00f1osa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharmacol Ther. 2018;47:605\u201314. https:\/\/doi.org\/10.1111\/apt.14494","journal-title":"Aliment Pharmacol Ther"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00341-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T14:58:20Z","timestamp":1723561100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-024-00341-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1038\/s41397-024-00341-2","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"4 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}